The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: A systematic review. (March 2021)

• Record Type: Journal Article
• Authors: Tonneau, Marion; Elkrief, Arielle; Pasquier, David; Paz Del Socorro, Thomas; Chamaillard, Mathias; Bahig, Houda; Routy, Bertrand
• Is Part Of: Radiotherapy and oncology. Volume 156(2021)
• Page Start: 1
• Page End: 9
• Publication Date: 2021-03
• Subjects: Radiation therapy -- Gut microbiome -- Mucositis -- Immuno-oncology -- Vancomycin; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2020.10.033
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: Composition of the gut microbiome modulates cancer immune set-points. Microbiome may trigger immune system to observe more systemic abscopal effect. Current evidence suggests that the gut microbiome influences radiotherapy efficacy. Gut microbiome is a key modulator in radiation-induced gastro-intestinal mucositis. Abstract: Radiation therapy (RT) is an essential component of therapy either curative or palliative armamentarium in oncology, but its efficacy varies considerably among patients through many extrinsic and intrinsic mechanisms of the tumour, which are beginning to be better understood. Recent studies have shown that the gut microbiome represents a key factor in the modulation of the systemic immune response and consequently on patients' outcome. Moreover, the emergence of biomarkers that are derived from the gut microbiota has fuelled the development of adjuvant strategies for patients treated with immunotherapy in combination or not with RT. Despite progress in development of more precise radiotherapy techniques, almost all patients undergoing RT to the abdomen, pelvis, or rectum develop acute adverse events as a consequence of several dose-limiting parameters such as the location of irradiation that may subsequently damage normal tissue including the intestinal epithelium. Several lines of evidence in preclinical models identified that vancomycin improves RT-induced gastrointestinal toxicities such as diarrhea and oral mucositis. In order to gain further insight into this rapidly evolving field, we have systematically reviewed the studies that have described how the gut microbiome may directly or indirectly modulate RT efficacy and its gastro-intestinal toxicities. Lastly, we outline current knowledge gaps and discuss potentially more satisfactory therapeutic options to restore the functionality of the gut microbiome of patients treated with RT.